Nanotherapeutics for Alzheimer's Disease with Preclinical Evaluation and Clinical Trials: Challenges, Promises and Limitations.
Sign Up to like & getrecommendations! Published in 2021 at "Current drug delivery"
DOI: 10.2174/1567201818666210910162750
Abstract: Alzheimer's disease (AD), a progressive and irreversible neurodegenerative disorder, is the most common form of dementia worldwide. Currently, there is no disease-modifying AD drug, and the development of effective treatments is made even harder by… read more here.
Keywords: preclinical evaluation; disease preclinical; nanotherapeutics alzheimer; evaluation clinical ... See more keywords